ClinicalTrials.gg
CompletedNCT06895876DPIPUpdated May 7, 2026

Deep Parasternal Intercostal Plane Block

An interventional study of Deep parasternal intercostal plane block in Nerve Block, sponsored by Institute Arnault Tzanck, France. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Institute Arnault Tzanck, France · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Cardiac surgery is a source of severe post operative pain witch can cause major respiratory complications due to non optimal post operative rehabilitation.

Multimodal analgesia provides acceptable pain control , but does not seem sufficient during coughing or mobilization. The use of morphine also exposes patients to side effects (nausea, vomiting, pruritus, respiratory depression, chronic pain, ileus). Bleeding and hemodynamic risks of peridural and spinal aneshesia limits their use.

The postoperative efficacy of deep parasternal intercostal plane block has not yet been evaluated sufficiently. The aim of this study is to evaluate the efficacity of TTMPB on the quality of postoperative recovery after cardiac surgery.

02

Conditions studied

  • Nerve Block

Keywords

  • Transversus thoracic muscle plane block
  • Cardiac surgery
  • Postoperative analgesia
  • Quality of recovery
  • QoR-15
03

In context

Lead sponsor

Institute Arnault Tzanck, France is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients requiring cardiac surgery with sternotomy

Exclusion criteria

Exclusion Criteria:

  • Emergency procedure
  • Procedures requiring lateral chest drainage
  • Hemodynamic instability
  • Severe kidney or liver failure
  • > 40
  • Chronic pain
  • Allergy to local anesthesics
  • Pregnant woman
  • Long term opioïds use
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Deep parasternal intercostal plane block

    The block is performed bilaterally in the 4th intercostal space. The probe is placed in the latero-median axis and a needle is placed latero-medially between the intercostal and transverse thoracic muscle. The solution is then injected under ultrasound control ()20 mL of 0,375% Naropeïne

    Procedure: Deep parasternal intercostal plane block

  • No intervention
    Control

    Standard multimodal analgesia

Interventions

  • ProcedureDeep parasternal intercostal plane block

    The block is performed bilaterally in the 4th intercostal space. The probe is placed in the latero-median axis and a needle is placed latero-medially between the intercostal and transverse thoracic muscle. The solution is then injected under ultrasound control

06

What researchers measure

Primary outcomes

  1. Quality of recovery 15 (QoR-15)

    QoR-15 score : 0 to 150. Addition of 15 items note between 0 to 10 150 = perfect post operative recovery possible 0 = worst post operative recovery possible

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Total morphine consumption at 24 hours

    Total morphine consumption, in milligrams, during the first 24 hours after surgery.

    Time frame: 24 hours after surgery

07

Study locations

1 site
  • Institut Arnault Tzanck
    Saint-Laurent-du-Var, 06700, France
08

References and documents

Publications

  • Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth. 1997 May;78(5):606-17. doi: 10.1093/bja/78.5.606. PubMed 9175983 ↗
  • Mangano DT, Siliciano D, Hollenberg M, Leung JM, Browner WS, Goehner P, Merrick S, Verrier E. Postoperative myocardial ischemia. Therapeutic trials using intensive analgesia following surgery. The Study of Perioperative Ischemia (SPI) Research Group. Anesthesiology. 1992 Mar;76(3):342-53. PubMed 1531742 ↗
  • Aydin ME, Ahiskalioglu A, Ates I, Tor IH, Borulu F, Erguney OD, Celik M, Dogan N. Efficacy of Ultrasound-Guided Transversus Thoracic Muscle Plane Block on Postoperative Opioid Consumption After Cardiac Surgery: A Prospective, Randomized, Double-Blind Study. J Cardiothorac Vasc Anesth. 2020 Nov;34(11):2996-3003. doi: 10.1053/j.jvca.2020.06.044. Epub 2020 Jun 18. PubMed 32665179 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Oct 2022, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2022
First posted
Mar 26, 2025
StartActual
Aug 10, 2022
Primary completionActual
Oct 12, 2022
CompletionActual
Jun 15, 2025
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06895876
Lead sponsor
Institute Arnault Tzanck, France
Responsible party
Marc LOPEZ, MD (Investigator principal, Institute Arnault Tzanck, France) — Principal investigator
First posted
Mar 26, 2025
Start date
Aug 10, 2022
Primary completion
Oct 12, 2022
Completion
Jun 15, 2025
Last update
May 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion